< Back to Press

USAGE OF CONTOUR®DIABETES APP SHOWN TO REDUCE THE LIKELIHOOD OF HYPOGLYCEMIC EVENTS IN PEOPLE WITH DIABETES, ACCORDING TO EUROPEAN STUDY PRESENTED AT THE ADVANCED TECHNOLOGY AND TREATMENTS FOR DIABETES MEETING 2019

Berlin, Germany

Today at the 12^th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD), Ascensia Diabetes Care has presented clinical research from the first European study to demonstrate that use of the CONTOUR^®NEXT ONE blood glucose meter in combination with the CONTOUR^®DIABETES app can reduce the likelihood of hypoglycemic events in people with diabetes.

The study was presented as a poster¹ at the ATTD 2019 in Berlin, Germany by Dr. Andreas Stuhr, M.D., Head of Global Medical Affairs at Ascensia and lead author. It examined the impact of usage of the CONTOUR^®NEXT ONE blood glucose meter and the CONTOUR^®DIABETES app on the likelihood of hypo- and hyperglycemic events after 180 days of meter and app use in two different groups of subjects from the UK and Germany.

The study found that meter and app usage for more than 180 days was associated with a statistically significant decrease in the likelihood of hypoglycemic events (defined as ≤50 mg/dL) in both UK and German cohorts, suggesting that the system can help people with diabetes manage their condition more effectively.

The study examined anonymized data from 11,341 people with diabetes from the UK (3,905 people) and Germany (7,436 people) to determine the effect of meter and app use for more than 180 days on the frequency of hypoglycemia and hyperglycemia.

Odds ratios were calculated to compare the frequency of hypoglycemia and hyperglycemia in the first 30 days with the frequency of these events after 180 days. An odds ratio of >1 means that use of the system reduced the chance of having a hypoglycemic or hyperglycemic event. In the UK cohort, the odds ratio for hypoglycemia was 1.412 and in the German cohort, the odds ratio for hypoglycemia was 1.364, both indicating a reduction in the likelihood of hypoglycemia after 180 days of meter and app usage. There was little effect observed on the frequency of hyperglycemia frequency (defined as ³180 mg/dL), with odds ratios of 0.99 in the UK cohort and 1.01 in the German cohort.

This is the first European study to demonstrate this effect from CONTOUR^®DIABETES app usage, and adds to evidence from a US study that was presented at the 28^th Diabetes Technology Meeting (DTM) in Bethesda, Maryland in November 2018², which demonstrated reductions in the likelihood of hypoglycemic and hyperglycemic events in people with diabetes following 180 days of CONTOUR^®DIABETES app use.

Dr. Andreas Stuhr, M.D., Head of Global Medical Affairs, Ascensia Diabetes Care, explained: “It is encouraging to see this new evidence in a European cohort of people with diabetes demonstrating that the CONTOUR^®DIABETES app can lead to improved glycemic control. The findings from this study show that by using the CONTOUR^®NEXT ONE meter and CONTOUR^®DIABETES app, people with diabetes may be able to decrease their likelihood of experiencing hypoglycemic events, which can in turn reduce the impact that diabetes has on their lives. Our aim at Ascensia is to empower people with diabetes to more effectively self-manage their blood glucose levels.” 

The CONTOUR^®DIABETES app is part of the CONTOUR^®NEXT ONE blood glucose monitoring system from Ascensia. The meter transmits blood glucose readings to the app via Bluetooth® technology on a compatible Android or iOS device^†. The app analyzes readings received from the meter to identify patterns and provides personalized guidance for diabetes self-management based on the well-researched Information-Motivation-Behavioral Skills (IMB) model of health behavior change. The CONTOUR^®DIABETES app is available in the Apple App Store (iOS) and Google Play (Android).

Click here to access an infographic about this study. 

ENDS

Notes for Editors

About Ascensia Diabetes Care

Ascensia Diabetes Care is a global specialist diabetes care company, dedicated to helping people living with diabetes. Our mission is to empower people living with diabetes through innovative solutions that simplify and improve their lives. We use our innovation and specialist expertise in diabetes to develop high quality solutions and tools that make a positive, daily difference for people with diabetes.

Home to the world renowned CONTOUR^® portfolio of blood glucose monitoring systems, our products combine advanced technology with user-friendly functionality that help people with diabetes to manage their condition. We are committed to continued research, innovation and development of new products and solutions. As a trusted partner in the diabetes community, we collaborate closely with healthcare professionals and other partners to ensure our products meet the highest standards of accuracy, precision and reliability, and that we conduct our business compliantly and with integrity.

Ascensia Diabetes Care was established in 2016 through the sale of Bayer Diabetes Care to Panasonic Healthcare Holdings Co., Ltd. Ascensia Diabetes Care products are sold in more than 125 countries. Ascensia Diabetes Care has around 1,700 employees and operations in 31 countries.

For further information, please visit the Ascensia Diabetes Care website at: http://www.ascensia.com.

Ascensia and Contour are trademarks and/or registered trademarks of Ascensia Diabetes Care. The Bluetooth word mark and logos are registered trademarks owned by Bluetooth SIG, Inc., and any use of such marks herein is under license. Apple and the Apple logo are trademarks of Apple Inc., registered in the U.S. and other countries. App Store is a service mark of Apple Inc. Google Play is a trademark of Google Inc.

About the CONTOUR^®NEXT ONE Blood Glucose Monitoring System:

The CONTOUR^®NEXT ONE system features an easy-to-use wireless-enabled smart meter that seamlessly connects to a smart mobile device via Bluetooth® connectivity. The meter provides immediate feedback through smartLIGHT technology and the CONTOUR^®DIABETES app collects, stores and analyses patient blood glucose results received from the meter. The app combines these results with other data recorded by the user, to provide detailed information about their condition that can help them understand how their everyday lives may impact their blood glucose readings. Through the app, users can also share the reports of their blood glucose results with their healthcare professionals, helping to create more informed and insightful discussions during their visits.

^†Compatibility information can be found at http://compatibility.contourone.com/.

For more information, please contact:
Joseph Delahunty
VP, Global Head of Communications, Ascensia Diabetes Care
joseph.delahunty@ascensia.com
+41-79-422-9286